PMID: 9545523Apr 18, 1998Paper

Appearance of cross linked proteins in human atheroma and rat pre-fibrotic liver detected by a new monoclonal antibody

Biochimica Et Biophysica Acta
H ItabeT Takano

Abstract

A new monoclonal antibody against malondialdehyde (MDA)-treated low density lipoprotein (LDL) was raised using homogenate of human atheroma as immunogen. This antibody, DLH2, was obtained by selecting the clones which did not react to native LDL but did react to copper-induced oxidized LDL (OxLDL). DLH2 showed a greater reactivity to MDA-LDL than to OxLDL. When LDL was treated with various aldehyde containing reagents, treatment of LDL with glutaraldehyde or MDA greatly increased the reactivity to the antibody, while LDL treated with 2,4-hexadienal or 4-hydroxynonenal was not reactive. Among many proteins tested, high density lipoprotein, bovine serum albumin and hemoglobin showed significant reactivity to DLH2 after they were treated with MDA or glutaraldehyde. When low density and high density lipoproteins treated with MDA were subjected to immunoblot analysis, newly formed products larger than the original apolipoproteins were detected with the antibody, suggesting that this antibody recognizes aggregated proteins with divalent short chain cross linkers. The antigenic materials were shown by immunohistochemical analysis to be present in foamy macrophages in human atheromatous lesions. DLH2 antigen did not colocalize either w...Continue Reading

References

May 12, 1975·Analytical Biochemistry·T G RedgraveC E West
Oct 1, 1992·Free Radical Biology & Medicine·H EsterbauerG Jürgens
Sep 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J A KampsT J van Berkel
Jun 22, 1992·Biochimica Et Biophysica Acta·W JessupR T Dean
Aug 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S KamimuraH Tsukamoto
May 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·M E RosenfeldJ L Witztum
Dec 1, 1991·The Journal of Clinical Investigation·J L Witztum, D Steinberg
Mar 1, 1988·Analytical Biochemistry·G M SmallP B Lazarow
Oct 1, 1985·Analytical Biochemistry·P K SmithD C Klenk
Apr 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A M FogelmanP A Edwards
Jul 1, 1995·The Journal of Clinical Investigation·H TsukamotoG M Brittenham
May 1, 1994·Atherosclerosis·E F GröneD Seidel
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K UchidaE R Stadtman

❮ Previous
Next ❯

Citations

Nov 7, 2008·Clinical Reviews in Allergy & Immunology·Hiroyuki Itabe
Jun 5, 2003·Experimental and Molecular Pathology·Craig D AlbrightCorneliu N Craciunescu
Nov 26, 1998·Progress in Lipid Research·H Itabe
Feb 13, 2001·Free Radical Biology & Medicine·D VayE Albano
Jul 17, 2012·Journal of Clinical Biochemistry and Nutrition·Hiroyuki Itabe
Sep 19, 2003·Biochemical and Biophysical Research Communications·Dmitri N SvistounovBard H Smedsrod
Oct 2, 2008·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Tatsuya TakanoEiko Fujita
Aug 2, 2001·Journal of Atherosclerosis and Thrombosis·H Itabe, T Takano
Aug 5, 2005·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yoichi Kudo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.